PT-141 is the research designation associated with bremelanotide, a cyclic heptapeptide studied as a melanocortin receptor agonist. “Heptapeptide” describes a peptide with seven amino-acid residues. [1] [2]
For laboratory and analytical research only. Not for human consumption, medical, diagnostic, therapeutic, or veterinary use.
Identity and research context
Rosen and colleagues reported a human study of PT-141 pharmacokinetics and pharmacodynamic measurements. The study concerns its own participants, material and protocol. It does not establish the suitability or effects of a catalog research product. [1]
Bremelanotide is the active ingredient in Vyleesi. FDA approval documentation dates that prescription-drug approval to June 21, 2019. The approved medicine and an AlphaGrade research listing are distinct products; shared compound nomenclature does not establish medicinal equivalence. [2] [3]
Documentation and lot traceability
Product- or lot-specific documentation may be available depending on the material and lot. Request the current lot’s documentation through Contact. Include the product name and the lot identifier from the label. Check that the document identifies the same material and lot before interpreting its results. A report for another brand or lot does not establish the properties of your material.
For PT-141, ask for the documented chemical identity and salt form. Do not infer acetate or another form from “PT-141” alone, or treat a nominal vial amount as an independently verified assay result.
AlphaGrade listings
Check each listing for current commercial details.
Frequently asked questions
Why does the literature use both PT-141 and bremelanotide?
PT-141 is a research designation; bremelanotide is the drug-substance name used in Vyleesi labeling. Neither name alone establishes the identity or quality of a particular lot. [1] [2]
Does Vyleesi’s approval apply to these research listings?
No. The FDA documentation identifies a specific prescription-drug product. It is not an approval or certification of the AlphaGrade listings.
References
- Rosen RC et al. (2004). Human PT-141 pharmacokinetic and pharmacodynamic study. Int J Impot Res. 16(2):135–142. DOI: 10.1038/sj.ijir.3901200. Primary-study record and abstract.
- FDA. Vyleesi prescribing information (2019). Official label.
- FDA. Vyleesi approval letter, June 21, 2019. Official approval letter.
The cited literature describes the compound or its components. It does not test, certify, or establish the suitability of any material supplied by AlphaGrade.
